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Introduction
Thalassemia major (TM) originated in Mediterranean,
Middle Eastern, and Asian regions, and sickle cell disease
(SCD) originated from throughout central Africa. However,
because of migration, both diseases now occur globally and
represent a growing health problem in many countries.1
Despite the remarkable improvements in medical therapy for
hemoglobinopathies,2,3 hematopoietic stem cell transplanta-
tion (HSCT) still remains the only available curative
approach. Although both TM and SCD are hemoglo-
binopathies, they are two distinct diseases requiring different
approaches to HSCT, based on their different clinical features
and course of disease. While transfusion dependency for TM
is a priori an indication for HSCT, the indications for HSCT
in SCD are less clearly defined because of the variability of
the disease course. The literature shows there is a wide expe-
rience in transplantation for TM, whereas only a few hundred
transplants have been performed for SCD.4,5 There are a num-
ber of possible reasons for this difference, including a lack of
consensus about the indications and time point for HSCT in
SCD, and the low chance of identifying an unrelated donor
for SCD patients.6,7 Table 1 shows the principal differences
between TM and SCD from the transplant perspective.
So far, only a few prospective clinical trials have been
reported in these diseases, and the decision to perform
HSCT and the details of transplant management remain
principally dependent on data derived from predominantly
retrospective investigations and on the clinical expertise of
Hematopoietic stem cell transplantation in thalassemia major 
and sickle cell disease: indications and management recommendations
from an international expert panel
Emanuele Angelucci,1 Susanne Matthes-Martin,2 Donatella Baronciani,3 Françoise Bernaudin,4 Sonia Bonanomi,5
Maria Domenica Cappellini,6 Jean-Hugues Dalle,7 Paolo Di Bartolomeo,8 Cristina Díaz de Heredia,9 Roswitha
Dickerhoff,10 Claudio Giardini,11 Eliane Gluckman,12 Ayad Achmed Hussein,13 Naynesh Kamani,14 Milen Minkov,2
Franco Locatelli,15 Vanderson Rocha,16 Petr Sedlacek,17 Frans Smiers,18 Isabelle Thuret,19 Isaac Yaniv,20
Marina Cavazzana,21,22,23,24 and Christina Peters;2,25 on behalf of the EBMT Inborn Error 
and EBMT Paediatric Working Parties 
1Hematology, Ospedale Oncologico di Riferimento Regionale “Armando Businco”, Cagliari, Italy; 2St. Anna Children’s Hospital,
Department of Pediatrics, Medical University, Vienna, Austria; 3Ospedale Oncologico di Riferimento Regionale “Armando Businco”,
Cagliari, Italy; 4Centre de Référence de Drépanocytose du CHI-Creteil, France; 5Hospital San Gerardo, Monza, Italy; 6Dipartimento di
Scienze Cliniche e di Comunità, IRCCS Foundation Policlinico Hospital, Milano, Italy; 7Service d’Hémato-Immunologie, Hôpital Robert
Debré, Paris, France; 8BMT-Center, Ospedale Civile, Pescara, Italy; 9Hopital Materno-Infantil Val d’Hebron, Barcelona, Spain; 10Paediatric
Unit for Haematology, Oncology and Immunology, University Düsseldorf, Germany; 11Hematology and Stem Cell Transplant Center,
Pesaro, Italy; 12Hôpital Saint Louis, Paris, France; 13King Hussein Cancer Center, Amman, Jordan; 14Division of BMT/Immunology,
Children’s National Medical Center, Washington, DC, USA; 15IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; 16Eurocord, Hôpital
Saint Louis, Paris, France; 17Department of Pediatric Hematology and Oncology Teaching Hospital Motol, 2nd Medical School, Charles
University Motol Prague, Czech Republic; 18Pediatric Hematology Oncology and Bone Marrow Transplantation WAKJC-LUMC, Leiden,
The Netherlands; 19Service d’Hématologie Pédiatrique Hôpital d'Enfants de la Timone, Marseille, France; 20Schneider Children's Medical
Center of Israel; 21U768 INSERM, Paris, France; 22Département de Biothérapie, AP-HP, Hôpital Universitaire Necker – Enfants Malades,
Paris, France; 23Université Paris Descartes, Sorbonne Paris Cité, IMAGINE Institute, Paris, France; 24CIC Biothérapie GHU Ouest, INSERM-
APHP, Paris, France; and 25EBMT Paediatric Diseases Working Party
©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.099747
Manuscript received on October 22, 2013. Manuscript accepted on December 23, 2013.
Correspondence: christina.peters@stanna.at
Thalassemia major and sickle cell disease are the two most widely disseminated hereditary hemoglobinopathies in
the world. The outlook for affected individuals has improved in recent years due to advances in medical management
in the prevention and treatment of complications. However, hematopoietic stem cell transplantation is still the only
available curative option. The use of hematopoietic stem cell transplantation has been increasing, and outcomes
today have substantially improved compared with the past three decades. Current experience world-wide is that
more than 90% of patients now survive hematopoietic stem cell transplantation and disease-free survival is around
80%. However, only a few controlled trials have been reported, and decisions on patient selection for hematopoietic
stem cell transplantation and transplant management remain principally dependent on data from retrospective analy-
ses and on the clinical experience of the transplant centers. This consensus document from the European Blood and
Marrow Transplantation Inborn Error Working Party and the Paediatric Diseases Working Party aims to report new
data and provide consensus-based recommendations on indications for hematopoietic stem cell transplantation and
transplant management.
ABSTRACT
the different transplant centers.8 For these reasons, the
EBMT Paediatric Diseases Working Party and Inborn
Error Working Party recognized the importance of estab-
lishing common guidelines. In October 2011, a
Consensus Committee was convened with the aim of
reviewing the literature and creating a consensus docu-
ment addressing the current treatment strategies for TM
and SCD. This paper summarizes the results of this
review and the panel’s recommendations on indications
and the approach to HSCT in these disorders.
Methodology
The committee panel was made up of experts jointly
selected by the European Blood and Marrow
Transplantation (EBMT) Inborn Error Working Party and
the Paediatric Diseases Working Party. It was composed of
20 members, with recognized clinical and scientific expe-
rience in HSCT and /or medical management of TM and
SCD. Members came from 18 institutions in 8 countries.
Pertinent published literature was identified from a
search using the terms “TRANSPLANTATION AND
THALASSAEMIA” or “SICKLE CELL DISEASE” using the
National Library of Medicine PubMed database. In addi-
tion, abstracts from recent international hematology and
annual stem cell transplant meetings (ASH, EBMT, and
CIBMTR), meetings of the EBMT Inborn Errors and
Paediatric Disease working parties and other educational
meetings were also reviewed for relevance, supplemented
by unpublished data from HSCT centers in Europe. The
consensus meeting was prepared in the six months pre-
ceding the meeting by two working groups for TM
(chaired by EA) and for SCD (chaired by SM). The two
working groups assessed and weighted evidence using the
GRADe approach for the two diseases separately from the
abovementioned sources.9 Each member of the respective
working group received a draft statement on the different
topics, and checked and revised the suggested recommen-
dations. During the final joint working group meeting, the
recommendation statements were discussed and
approved. Subsequently, a draft manuscript was sent to all
committee members and was finally accepted by all of
them. Any industrial influence on the process of consen-
sus development was avoided. 
Thalassemia major
HSCT in children and adolescents
Thirty years have elapsed since the first HSCT was per-
formed for patients with TM, and allogeneic transplanta-
tion in TM is now accepted as standard clinical practice.10
In the 1980s and early 1990s, more than 1000 TM
patients were transplanted at the transplant center in
Pesaro, Italy. They reported a 20-year probability of tha-
lassemia-free survival of 73% in 900 consecutive unse-
lected patients transplanted from an HLA-identical sibling
donor.11 Subsequently, several centers worldwide have
started their own transplant programs.12-29 Recent results
show that, with modern transplantation approaches, and
careful patient selection, even better results could be
obtained (Table 2). At the same time, however, survival
without transplantation of TM patients has improved as
the result both of a better understanding of the patho-
physiology of iron overload and improvements in the
medical therapy of TM; survival into the fourth or fifth
decade of life is now possible for well-treated patients.30
Moreover, the first successful use of the long-awaited
gene therapy approach has recently been reported, and
the possibility that in a not so remote future gene therapy
will become available for TM patients must also be
included in the evaluation.31 However, the availability of
optimal conventional medical therapy and the prospect of
gene therapy are both limited to industrialized countries
with longstanding experience where only a minority of
TM patients live. Thus, at present, transplantation
remains the only available curative approach for TM, but
its role needs to be carefully evaluated, particularly in a
global setting.
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Table 1. Major differences between thalassemia major (TM) and sickle cell disease (SCD) on HSCT perspective.
Thalassemia Sickle cell disease
Prognostic criteria for disease severity Homogenous pattern for β thalassemia major Wide genetic variability; inconsistent development
of  complications
Currently accepted indication for Transfusion dependency. For patients with an HLA Patient with matched sibling donor and 
allogeneic HSCT identical sibling donor or well-matched related or complication requiring treatment with hydroxurea
unrelated donor: as soon as possible to avoid or transfusion
transfusion associated complications
Total number of HSCT reported > 3000 patients transplanted 500-600 patients transplanted
Risk factors for transplant-related Age, organ dysfunction due to iron overload Age, history of cerebral events
complications
Alternative effective medical therapy Life-long transfusion with chelation Hydroxyurea: not curative, but ameliorates some 
complications. Chronic transfusion and chelation 
therapy.
Key issue for transplant outcome Control of iron overload and related tissue damage Cure from chronic inflammation and prevention 
of future SCD-related organ damage
Conditioning regimen Needs to ablate an expanded bone marrow Reduced intensity regimens seem to induce 
stable chimerism and full donor erythropoiesis
Possibility for gene therapy First successful case reported. Phase I clinical  No successful case reported. Phase I clinical trial 
trial  ready to start ready to start
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Table 2. Recent reports on matched sibling donor HSCT in children and adults with thalassaemia major. 
Author and N. of Patient cohort/ Overall survival Thalassemia Treatment related Comments
Reference patients Pesaro risk category free survival  mortality
Galambrun et al.12 108 Children all categories 15 years 15 years 15 years 96 sibling donor 
of risk 86.8% 69.4% 12% Regimen: Bu-Cy ±ATG
Yesilipek et al.13 245 Children: 1 year 1 year 1 year 88 BM, 137 PB, 20 CB 
Low: 41 85% 68% 7.75% Regimen: Bu-Cy
Intermediate: 130
High: 63 
Li et al.14 82 Children all risk categories 3 years 3 years 3 years 52 MUD, 30 sibling 
91% 87% 8% Regimen Bu-Cy-Thiotepa, 
Fludarabine.
Choudhary et al.15 28 Children: 78.5% 71.4% 21.4% Regimen: Treosulfan-
Intermediate risk: 7 Thiotepa-Fludarabine.
High risk: 21
Bernardo et al.16 60 Low: 27 5 years 5 years 7% 20 sibling donor, 40 MUD.
Intermediate: 17, High: 4 93% 84% Regimen Treosulfan - 
Adults: 12 Thiotepa - Fludarabine
Sabloff et al.17 179 Low: 2% 5 years: 5 years Intermediate risk: Bu-Cy + ATG in 77, 
Intermediate: Intermediate risk: Intermediate risk: 5/75 Bu-Cy in 102
42% 91% 88% High risk 
High: 36% High risk: 64% High risk: 62% 23/64
Ghavamzadeh et al.18 183 Children 2 years 2 years 1 year 87 PBSC , 96 BM 
Low and intermediate PBSCs 83% PBSCs 76% PBSC 14% Regimen: Bu-Cy
BM 89% BM 76% BM: 9%
Iravani et al.19 52 Children high risk: 52 4.1 years 4.1 years 4.1 years 32 BM, 20 PBSC
80% 65% 7/52 Regimen: Bu-Cy
Irfan et al.20 56 Children 5 years 5 years 100 days: 29 BM, 27 PBSCs
Low: 20 BM: 73% BM: 67% 10/56 Lower risks: Bu-Cy
Intermediate : 20 PBSCs: 65% PBSCs: 55% High risk: Hydroxyurea-
High: 16 Azathioprine-Fludarabune-
Bu-Cy
Locatelli et al.21 259 Median age 8 years (range 1-24) 6 years 6 years 4% Multicentric retrospective
Low: 86 95% 86% registry study.
Intermediate: 122 Regimens: Bu-Cy, 
High: 51 Bu-Cy_Fludarabine, Bu-Cy-
Thiotepa ±ATG.
Ullah et al.22 48 Low: 31 6 years 6 years 20.8% Regimen: Bu-Cy
Intermediate: 11 79% 75%
High: 6
Di Bartolomeo et al.23 115 All categories 20 years 20 years 1 year 20 years Pescara 
89.2% 85.7% 8.7% experience.
Regimen: Bu-Cy
Gaziev et al.24 107 High risk 12 years 12 years 37% Regimen: Bu-Cy or
66% 62% Hydroxyurea-Azathioprine-
Fludarabine-Bu-Cy
Lawson et al.25 55 Low: 17 8 years 8 years 5,4% Regimen: Bu-Cy±Campath 
Intermediate: 27 94.5% 81.8% or Fludarabine
High: 11
Gaziev et al.26 68 6 low risk 3 years 3 years 100 days  Intravenous Busulfan 
23 intermediate risk 91% 87% 3% based regimen
39 high risk
Chiesa et al.27 53 high risk children 2 years 2 years 2 years Intravenous Busulfan
96% 88% 4% dose-adjustment policy.
Hussein et al.28 44 Low risk: 7 5 years 5 years 1 patient died High risk patients received 
Intermediate risk: 24 97.8% 86.4% reduced intensity 
High risk: 13 conditioning and had higher
thalassemia recurrence rate (23%)
Mathews et al.29 50 High risk 3 years 3 years 13% Treosulfan based conditioning
86.6% 77.8%
OS: overall survival; TFS: thalassemia free survival; TRM: transplant related survival; NR: not reported; Bu: busulfan; Cy: cyclophosphamide; ATG: antithymocyte globulin; BM: bone
marrow; PBSC: peripheral blood stem cells; CB: cord blood.
The Pesaro experience has clearly indicated that patient
status at time of transplantation is the critical element pre-
dicting outcome. This was formalized with the identifica-
tion and the adoption in the clinical practice of three risk
factors and three risk classes.32 In the last decade, almost
all transplant centers have followed this simple classifica-
tion to predict the risks and benefits of HSCT in TM
patients and perform HSCT in the first years of life before
iron-related complications have developed.
In addition to this, transplantation techniques have
improved and transplantation-related mortality (TRM) has
fallen to 5% or even lower in young low-risk children
transplanted from an HLA-matched sibling donor (MSD)
(Table 2). In a large EBMT survey of 1061 cases of MSD-
transplantation performed in the last decade, overall sur-
vival (OS) and disease-free survival (DFS) were 91±0.01
and 83±0.01 months, respectively. Moreover, in this report
there was a significant age threshold of 14 years for opti-
mal results (96% vs. 82% and 86% vs. 74% for OS and
DFS, respectively).33
The use of peripheral blood stem cell transplantation
(PBSCT) from MSD instead of bone marrow (BM) has
been proposed to prevent graft failure in TM. Four studies
report this type of transplant in TM. Overall, 886 patients
receiving PBSCT have been described with substantially
the same conclusions: the procedure is feasible in high-risk
patients, with one study showing some advantages of
PBSCT, but three studies showed an increased risk of
chronic graft-versus-host disease (GvHD).18-20 Recently, the
fourth study reported from a Chinese group demonstrated
no difference in terms of rate of acute and chronic GvHD
using a novel conditioning regimen.14
In 2003, Locatelli et al. first reported the feasibility of
using HLA-identical sibling cord blood (CB) for HSCT in
TM.34 This kind of allograft was associated with a
decreased risk of both acute GvHD (aGvHD) and chronic
GvHD (cGvHD) and of TRM, provided the CB unit had an
adequate number of nucleated cells (i.e. > 3.5x107/kg). A
large, international study retrospectively comparing CB to
BM recipients has recently been completed. Analyses
showed that OS, DFS, acute and chronic GvHD were
95%, 88%, 20%, and 12%, respectively for BM recipients
(n=389), and 96%, 81%, 10%, and 5%, respectively for
CB recipients (n=70). In this cohort, the cell dose (median
3.9x107/kg) did not influence outcome of patients given
cord blood.21
Recommendations
• Young TM patients with an available HLA identical sibling
should be offered HSCT as soon as possible before development
of iron overload and iron-related tissue damage.
• Transplant-related risk factors should be evaluated according
to the Pesaro risk score. 
• HLA genoidentical CB and BM are equally effective stem
cell sources.
• PBSCT should be avoided because of the increased risk of
cGVHD.
HSCT in adult patients 
Experience of HSCT in adult patients remains very lim-
ited, with very few centers performing HSCT in patients
over the age of 18 years, and with TRM being persistently
around 25%.24
The Pesaro experience demonstrated that constant con-
trol of iron overload is the main factor determining trans-
plant outcome.35 As medical therapy of TM has improved
substantially over the last years, and, therefore, nowadays
adult patients are in a much better condition compared to
those who underwent HSCT in the past, outcome after
HSCT should also improve.36,37
Recommendations
• HSCT in adults who have been well-chelated since infancy
should be offered within controlled trials.
• Assessment of clinical condition according to the Pesaro risk
score and adequate transfusions/chelation regimen are the major
issues to be evaluated before deciding to perform HSCT.
Use of donors other than an HLA matched sibling 
On average, 25-30% of patients have an available MSD.
However, in China, because of the ‘one-child’ policy, the
possibility of having an MSD will remain unchanged. In
contrast, in countries with large families, the likelihood of
finding an MSD could be as high as 60-70%.38
So far, the experience of HSCT from HLA-disparate rel-
atives is limited and the results are much inferior to those
obtained with an HLA-identical sibling as donor.39
Recently, important results have been published from a
small series using related donors who were not MSD (11
pheno-identical and 5 1-antigen mismatched related
donors) using a pre-conditioning phase with hydroxyurea,
azathioprine and fludarabine and a conditioning regimen
including busulfan, thiotepa, cyclophosphamide and rab-
bit ATG. In this series, TM-free survival was 94%.40 The
option of a haploidentical related donor has been explored
in a limited series (n=22) of heterogeneous TM patients
using a haploidentical related donor and a “megadose” of
positively-selected CD34+ cells.41
Recommendations
• HSCT from an HLA-mismatched family member in TM
should still be considered an experimental approach and has to
be conducted in the context of well-designed controlled trials.
• HLA typing of of the entire family is advisable. HSCT from
an HLA-phenotypically-identical donor is an option to be per-
formed in expert centers.
Matched unrelated donors 
A number of studies have shown that unrelated-donor
(UD)-HSCT can cure a large proportion of patients with
TM, provided that the UD is selected using high-resolu-
tion molecular typing for both HLA class I and II mole-
cules and according to stringent criteria of compatibility
with the recipient (i.e. identity or single allelic disparity for
the loci for HLA-A, B, C, DRB1, and DQB1 loci).42 Using
this approach, a suitable donor can be found in approxi-
mately one-third of Caucasian patients with TM; a higher
probability could be expected in China because of the rel-
atively genetic homogeneity of the Chinese population.14
In addition, the risk of rejection can be reduced by select-
ing UD who do not have non-permissive mismatches at
HLA-DPB1 locus in the host-versus-graft direction.43
Recommendations
• If a well-matched UD is available, allogeneic HSCT is a
suitable option for a child with life-long control of iron overload
and absence of iron-related tissue complications.
• The UD must be selected using high-resolution molecular
typing for both HLA class I and II loci, and according to stringent
criteria of compatibility with the recipient.
E. Angelucci/S. Matthes-Martin et al.
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Unrelated cord blood transplantation
The use of unrelated cord blood transplantation (UCB)
as source of stem cells in TM has not been explored in
well-designed clinical trials. Evaluation of reported results
is hampered by differences in single center experience,
conditioning regimens and accepted degree of HLA dispar-
ity. Recently, Jaing et al. reported results of UCBT in 35
TM patients. OS was found to be 88%, while DFS was
74%. The cumulative incidence of TRM was 11%. These
remarkably good results are likely attributable to the high
number of total nucleated cells/kg infused (7.8x107/kg).44
Combining data from 3 different registries, Ruggeri et al.
found the outcome of UCBT in TM to be much less favor-
able; in 35 TM patients, an OS of 62% with a DFS of only
21% was reported. The cumulative incidence of graft fail-
ure was 52%.45
Recommendations 
• Unrelated cord blood transplantation must be performed in
the context of well-controlled clinical trials in centers with specific
UCBT programs.
Transplant management 
Conditioning regimen 
The biological aspects of allogeneic HSCT in TM are
different from those for hematologic malignancies. There
is no necessity to eradicate a malignant clone and the
graft-versus-tumor effect is not required.11 Moreover, TM
patients have not received previous chemotherapy and
their immunological system is not impaired. TM patients
have a hypercellular and expanded marrow.46 Additionally,
in adolescent or adults undergoing HSCT, sensitization to
red blood cell antigens may have occurred, possibly
together with development of anti-HLA antibodies.47 In
these circumstances, the ideal conditioning regimen
should be capable of eradicating the diseased marrow and
be sufficiently immunosuppressive to permit a sustained
engraftment. For many years, the preferred regimen
included oral busulfan (Bu) at 14 mg/kg and cyclophos-
phamide (Cy) at 120-200 mg/kg. The addition of azathio-
prine, hydroxyurea and fludarabine to the BuCy regimen
made an important contribution to improving the results
in high-risk patients.48 In the last decade, new conditioning
regimens for TM patients have been introduced with
improved results, such as intravenous Bu, or treosulfan
associated with thiotepa and fludarabine.14,16 Particularly
fludarabine has been included in the conditioning regimen
by several groups in the last decade with low TRM and
reduced rejection risk (Table 2).
To overcome the non-negligible TRM and morbidity,
especially in high-risk or adult patients, reduced intensity
conditioning (RIC) regimens have been tested.49,50
Although transplant-related toxicity was minimal, many
patients showed only transient and incomplete engraft-
ment, and most ultimately developed graft rejection, thus
indicating that TM patients need a more intensive, mye-
loablative conditioning regimen (MAC).29,51 However, to
avoid the well-known late effects of radiotherapy on the
growing organism, and in particular the risk of secondary
malignancies, irradiation should not be an option for non-
malignant disorders.52
A newer experience has shown that approximately
11% of transplanted patients develop long-term, stable
mixed chimerism (MC) after HSCT.53 This percentage is
higher in patients given CB transplantation from an HLA-
identical relative.54 MC patients, despite the limited
engraftment (even if no higher than 20%), may achieve a
functioning graft status characterized by a normal hemo-
globin level, no red blood cell transfusion requirement, no
increment in iron stores, and a limited degree of erythroid
hyperplasia which is not of any clinical relevance.55 Thus
the disease can be adequately controlled without com-
plete eradication of the pathological hematopoiesis.
Another tool to prevent graft failure could be the system-
atic use of antithymocyte globulin (ATG) in addition to an
MAC.12
Recommendations 
• MAC without irradiation should always be used for stan-
dard transplantation. In case of BU-containing regimen, intra-
venous formulation should be used.
• Reduced toxicity regimens are under investigation and are to
be used in the context of clinical trials.
• Any prospective attempt to induce stable MC should be con-
sidered experimental.
Graft-versus-host disease prophylaxis 
The preferred GvHD prophylaxis in the majority of
published studies of HSCT from matched sibling donors
consisted of cyclosporine and methotrexate (4 doses intra-
venous (IV) on Days +1, +3, +6 and +11 post transplanta-
tion).48 The addition of ATG to this regimen was success-
fully used both in HLA-identical sibling HSCT recipients
and, especially, in those transplanted from an unrelated
volunteer or an HLA-partially matched relative.56,57
Recommendations 
• The combination of cyclosporine and methotrexate represents
the gold standard for GvHD prophylaxis for HSCT from MSD.
• Mono- or polyclonal antibodies like ATG or alemtuzumab
could contribute to better prevent  rejection and GVHD in the
context of MSD HSCT and should be explored in prospective
trials.
• These antibodies should be routinely used for GVHD pre-
vention in non-sibling HSCT.
Sickle cell disease
Sickle cell disease (SCD) is associated with substantial
morbidity, leading to both reduced quality of life and
shortened life expectancy.58-63 Survival has improved sig-
nificantly in the last two decades and 94% of children
with SCD now survive until the age of 18 years thanks to
better surveillance, pneumoccocus vaccination, penicillin
prophylaxis and treatment with hydroyurea.64,65 However,
mortality is still significant once patients reach adult-
hood.61,66
SCD-associated morbidity and mortality in young
adults is largely due to as yet unpreventable complications
such as priapism, avascular necrosis, chronic pulmonary
impairment, hypertension, stroke and recurrent veno-
occlusive crises.58,67-70
The only curative approach for SCD is HSCT.
Historically, the indication for HSCT in SCD was mainly
based on SCD-associated morbidity: the sicker the child,
the stronger the indication.71 With the reduction in TRM in
recent years, and with the increasing knowledge of the
severity of complications in untreated patients, the accept-
ed indications for HSCT have become less restrictive.72,73
HSCT in thalassemia major and sickle cell disease 
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Matched sibling transplantation  
In the last ten years, the outcome data of more than 200
patients who underwent HSCT from an HLA-matched
sibling donor have been analyzed and published. OS was
found to be around 95%.72-75 Bernaudin et al. reported 121
patients transplanted in France after 2000 with a DFS of
95% at three years.76 Taking into account that: 1) overall
survival has become equal or even better in patients who
undergo HSCT compared to those on supportive treat-
ment, and disease-free survival is over 95%; 2) disease-
related morbidity and mortality are increasing with age,
and event-free survival following HSCT is significantly
better in patients transplanted before developing SCD-
related organ damage; and 3) in children, TRM increases
with age, the use of early HSCT is justified in children
with any SCD-associated symptoms or event.5,64,77 Young
adults who experience more severe disease as they get
older also benefit from HSCT.78 However, severe chronic
GvHD has been described following HSCT in heavily-
transfused end-stage adult SCD patients.79
The main obstacle for HSCT in patients with SCD is the
restricted donor availability. Overall, only 18% of patients
with SCD have a healthy matched sibling donor, and the
probability of finding a matched unrelated donor is
extremely low.80
It has been shown that the incidence of chronic GvHD
following matched sibling HSCT for non-malignant dis-
eases is significantly higher in patients receiving PBSC as
compared to BM.81,82 This justifies the recommendation
that BM be employed for transplanting SCD patients. Very
promising results with a low rejection rate and a low risk
of GvHD in patients with SCD transplanted with related
UCB have been published by Locatelli et al.34
Recommendations
• Young patients with symptomatic SCD who have an HLA-
matched sibling donor should be transplanted as early as possi-
ble, preferably at pre-school age.
• Unmanipulated BM or UCB (whenever available) from
matched sibling donors are the recommended stem cell source.
Alternative donor transplantation 
Even if results of matched unrelated HSCT can be
expected to be comparable to those obtained in TM, due
to the lack of matched donors in the registries there are no
firm data on outcome of HSCT from UD for SCD, and,
therefore, the advantages and disadvantages of this option
cannot be adequately addressed.
For many patients, however, a 4/6 or higher HLA-
matched unrelated CB unit can be found. In France, a large
effort is being undertaken to set up a programme of ‘tai-
lored’ CB banking in SCD-affected families. The CB units
not HLA compatible with the affected sibling are cryopre-
served so that to establish representation of the ethnic
minority (patients of African descent) in the French CB
banks (M Cavazzana, personal communication, 2014). So far,
a total of 32 patients with SCD transplanted with an UCB
unit have been published, 18 of them following an RIC
regimen, with an overall survival of 91%, but a disease-
free survival of only 50% because of rejection.7,45,83,84 The
Sickle Cell Unrelated Donor Transplant Trial (SCURT
trial) of the Blood and Marrow Transplant Clinical Trials
Network (BMT CTN) was a phase II study on the toxicity
and efficacy of UCB or BMT in children with severe SCD
using RIC. Eight children with severe SCD underwent
unrelated donor CB-transplantation following alem-
tuzumab, fludarabine, and melphalan. Three patients who
engrafted had 100% donor cells by Day 100 which was
sustained, while 5 patients had autologous hematopoietic
recovery. Based upon this high incidence of graft rejection,
enrolment into the CB arm of the SCURT trial was sus-
pended. However, because this RIC has demonstrated a
favorable safety profile, the trial remains open to enrol-
ment for unrelated BMT.7 Another concern to be consid-
ered is the high incidence of chronic GvHD in the context
of unrelated CBT.85 
Recently, promising results from haploidentical HSCT
following an RIC regimen have been published.86
However, for both unrelated CB and haploidentical HSCT,
rejection remains a major obstacle in the context of RIC.
Recommendations
• SCT from unrelated BM or CB donors should only be con-
sidered in the presence of at least one of the indications suggested
by Walters et al.,71 and should be performed only in the context of
controlled trials in experienced centers (Table 3).
Transplant management 
Conditioning regimen 
The most widely used myeloablative conditioning regi-
men for patients with SCD consists of busulfan 14-16
mg/kg and cyclophosphamide 200 mg/kg +/- ATG.34,73-75
Growth does not seem to be impaired following myeloab-
lative conditioning as long as it is not performed near or
during the adolescent growth spurt. However, the risks of
infertility and secondary neoplasm are a major con-
cern.34,74,87 Cryopreservation of sperm and ovarian tissue,
respectively, has been proposed.88,89 HSCT following an
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Table 3. Indication for allogeneic HSCT suggested by Walters et al. 
Stroke or central nervous system event lasting longer than 24 h, acute chest syndrome with recurrent hospitalizations or previous exchange transfusions
Recurrent vaso-occlusive pain (more than 2 episodes per year over several years) or recurrent priapism
Impaired neuropsychological function with abnormal cerebral MRI scan
Stage I or II sickle lung disease
Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate 30 to 50% of the predicted normal value)
Bilateral proliferative retinopathy with major visual impairment in at least one eye
Osteonecrosis of multiple joints
Red-cell alloimmunization during long-term transfusion therapy
RIC regimen is currently being evaluated in several cen-
ters. Small patient series using mainly fludarabine-based
regimens have shown promising results with an OS of
100% and a DFS of 95%.78,90,91 The use of either alem-
tuzumab (Campath-1H) or ATG in the context of RIC
seems to be indispensable for stable engraftment.92 In
Austria, a cohort of 8 patients underwent matched sibling
HSCT following conditioning with fludarabine, melpha-
lan, thiotepa and ATG or Campath-1H with a disease-free
survival of 100% and stable engraftment.93
Recommendations
• The gold standard for conditioning in patients with SCD is
busulfan, cyclophosphamide and ATG.
• RIC regimen should be explored in and confirmed by
prospective trials.
Graft-versus-host disease prophylaxis
A survey on patient perception of HSCT with RIC per-
formed by Chakrabarti et al. showed that chronic GvHD
was considered unacceptable for 80% of patients with
SCD.94 With the use of ATG, cyclosporine A and MTX an
incidence of over grade II aGvHD between 11% and 44%
and an incidence of cGvHD between 6% and 44% has
been reported.34,72,74 Two small series have been published
on the combination of RIC and alemtuzumab and no
aGvHD or cGVHD was reported.78,90 The use of alem-
tuzumab in the context of RIC seems, in effect, to be asso-
ciated with a lower incidence of acute and chronic GvHD,
but at the price of an increased incidence of viral compli-
cations.95
Recommendations
• The use of ATG and post-transplantation cyclosporine A
plus MTX is the gold standard for patients with SCD following
myeloablative conditioning.
Follow-up evaluation and chimerism testing  
for TM and SCD
A standardized pre-transplantation assessment based on
existing standards for TM and SCD care, and individual-
ized re-assessment post transplantation, are a prerequisite
for objective evaluation of the impact of HSCT in terms of
improvement or reversal of pre-transplantation morbidity.
All TM and SCD-specific conditions must be addressed
and treated if necessary (e.g. iron overload in TM and vas-
cular impairment in SCD). As demonstrated, persistent
MC does not impact DFS and OS either in TM or in SCD;
however, chimerism should be regularly checked in both
diseases after HSCT.34,75,78,90
Recommendations
• Post-transplantation evaluation and care should be undertak-
en in cooperation with hematologists experienced in TM or SCD.
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Table 4. Recommendation summary for HSCT in TM.
Indication Transfusion dependency
Time of transplantation: With HLA-identical sibling: as soon as possible
Stem cell source from MSD: Bone marrow, cord blood
HSCT in adult TM patients: If sufficient chelation was performed; within controlled  clinical trials only
HSCT from HLA-mismatched family members: Within controlled clinical trials only
HSCT from phenotypically identical family members: In TM-experienced HSCT-centers only
HSCT from unrelated donors Only from allelic matched donors; in patients without iron-related tissue damage
HSCT with unrelated cord blood Within controlled clinical trials only, in expert centers for CBT
Conditioning regimen: Standard: myeloablative without irradiation
Reduced: within controlled clinical trials only
GVHD-prophylaxis for MSD-HSCT Standard: CSA + MTX; antibodies (ATG, alemtuzumab) as rejection- and GVHD-prophylaxis:
within controlled clinical trials
GVHD-prophylaxis for non MSD-HSCT: CSA, MTX + antibodies
MSD: HLA-identical sibling donor; HSCT: hematopoietic stem cell transplantation; CBT: cord blood transplantation; GVHD: graft-versus-host disease; CSA: cyclosporine A; 
MTX: methotrexate; ATG: anti-thymocyte globulin.
Table 5. Recommendation summary for HSCT in SCD.
Indication for MSD-HSCT Symptomatic SCD
Time of transplantation: With HLA-identical sibling: as soon as possible
Stem cell source from MSD: Bone marrow, cord blood
Indication for HSCT from unrelated BM or CB donors: At least one criteria according Walters et al. (Table 3)
Within controlled clinical trials only
Conditioning regimen: Standard: IV Busulfan, cyclophosphamide, ATG
Reduced: within controlled clinical trials only
GvHD-prophylaxis for MSD-HSCT Standard: CSA + MTX; antibodies (ATG, alemtuzumab) as rejection- and GvHD-prophylaxis
Post-transplant evaluation: In cooperation of hematologists and transplant experts 
MSD: HLA-identical sibling donor; HSCT: hematopoietic stem cell transplantation; GvHD: graft-versus-host disease; CSA: cyclosporine A; MTX: methotrexate; ATG: anti thymo globuline. 
Cost and cost effectiveness for TM and SCD patients 
The care of TM, both by transplantation and medical
therapy, has dramatically improved during recent decades.
However, this improvement has been limited to patients
living in industrialized countries, while the large majority
of patients are born and live in other, non-industrialized
countries.96 TM care is a complex, multidisciplinary and
expensive tool requiring dedicated and experienced units.
From a global health perspective, in some countries, TM
represents an enormous burden of care. For example, in
Cyprus it was calculated in the 1970s that in 40 years
80,000 units of blood would be needed annually to trans-
fuse the country's TM patients and the overall cost would
exceed the total national health budget.97 An Italian study
investigated the cost/benefit estimation from a societal
perspective and quantified tariffs, expenses and net
income in 2006 for TM patients. The mean costs were 
€ 1242/patient/month, 55.5% attributed to iron chelation
therapy and 33.2% attributable to transfusions.98
Moreover, proper medical therapy for TM requires
advanced technologies such as cardiac or hepatic MRI.30,99
With the combined cost of blood transfusions, chelation
and management of complications, the requirements for
optimal thalassemia care clearly exceed the health
resources available in most non-industrialized countries.
For SCD, it has been calculated that 50,000 patients in
the USA need more than 100,000 hospital admissions per
year with associated costs of approximately US$ 10,000
US/SCD patient/year.100 Kauf et al. calculated that the aver-
age lifetime cost of care was US$460,151/SCD patient.
These data compare to the costs of HSCT from sibling
donors for non-malignant diseases of US$ 112,000-
150,000 US, which would translate into US$ 1900
US/expected life year in case of HSCT in infancy.101 In con-
clusion, for both TM and SCD, HSCT is cost-effective in
comparison to life-long supportive therapy.
Conclusion 
Hematopoietic stem cell transplantation currently
remains the only available curative treatment for hemo-
globinopathies. In contrast with some recommendations,
our group strongly suggests early transplantation for TM
and SCD if a suitable donor is available and if the patient
can be treated in an experienced transplantation center.
The development of improved supportive care, including
transfusion services, chelation therapy and prevention of
infectious complications, does not modify this position.
However, much more uncertainty applies to the complex
challenge of where to place the curative, but potentially
lethal, HSCT treatment as an alternative to a medical, non-
curative therapy in adults and patients with advanced dis-
ease. Transplantation outcomes today are much improved
compared with the 1980s and 1990s, with more than 90%
of patients surviving transplantation and more than 80%
of them being disease-free after having been treated in a
number of different centers worldwide, including centers
outside industrialized countries. If in the future gene ther-
apy could provide a cure, it needs to demonstrate at least
equivalent results in terms of cost/benefit ratio with
HSCT, which is today a widely applied, standard practice
for the cure of hemoglobinopathies.
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